{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:05:02Z","timestamp":1779433502418,"version":"3.53.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Herpes zoster, an infectious disease resulting from the reactivation of the varicella-zoster virus, is characterized by intense neuropathic pain. Safe and effective vaccination remains the optimal strategy for preventing and reducing associated complications. Recombinant zoster vaccine (CHO cell) (Qiuhong et\u00a0al) employs a novel adjuvant system, BC02. This study aimed to conduct a comprehensive non-clinical safety assessment of RZV in adult Sprague-Dawley rats to support its entry into clinical trials. The rats received four (sp, one additional dose beyond the intended clinical three-dose schedule) doses of RZV. Safety was assessed using general health observations, immunotoxicity and immunogenicity assays, hematological and biochemical profiling, and histopathological evaluations. Aside from the changes observed in the adjuvant control group, no significant toxic effects were detected. No distinct target organs of toxicity were identified. The no-observed-adverse-effect level (NOAEL) was 1.0 mL per rat, which is equivalent to two human doses. The vaccine also elicited strong cellular and humoral responses, indicating its favorable immunogenicity. In summary, this systematic toxicology program supports the safety, tolerability, and immunogenicity of RZV and justifies its progression to human clinical trials.<\/jats:p>","DOI":"10.3389\/fcimb.2026.1756776","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:09:15Z","timestamp":1779430155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Repeated dose toxicity and immunogenicity studies in SD rats: a new recombinant zoster vaccine (CHO cell) formulated with adjuvant BC02"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Yang","sequence":"first","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control","place":["Beijing, China"]},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA)","place":["Beijing, China"]},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ge","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Deng","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Hu","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faqin","family":"Liang","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Lu","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pansheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Tan","sequence":"additional","affiliation":[{"name":"Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Huang","sequence":"additional","affiliation":[{"name":"Center of Safety Evaluation and Research, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking vaccine adjuvant mechanisms of action to function","volume":"10","author":"Ben-Akiva","year":"2025","journal-title":"Sci. Immunol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd006866.pub3","article-title":"Antiviral treatment for preventing postherpetic neuralgia","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1201\/9781003155447-39","article-title":"Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus","volume":"13","author":"Cole","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci175378","article-title":"Advances in understanding the mechanism of action of adult vaccines","volume":"133","author":"Cunningham","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-0716-1892-9_8","article-title":"Developments in vaccine adjuvants","volume":"2412","author":"Firdaus","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1007\/978-3-319-44348-5_24","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biom14070739","article-title":"Exploring the link between varicella-zoster virus, autoimmune diseases, and the role of recombinant zoster vaccine","volume":"14","author":"Ishihara","year":"2024","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.21203\/rs.3.rs-6370541\/v1","article-title":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults \u226550 years of age: a randomised, active-controlled, non-inferiority trial","volume":"16","author":"Jin","year":"2025","journal-title":"Nat. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/s2666-7568(22)00039-3","article-title":"Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2278362","article-title":"Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies","volume":"19","author":"Mwakingwe-Omari","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B12","first-page":"99","article-title":"Research progress on novel BC adjuvant systems","volume":"37","author":"Qiuhong","year":"2024","journal-title":"Chin. J. Biologicals"},{"key":"B13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: from mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"Itc19","DOI":"10.1007\/978-1-4757-2705-0_55","article-title":"Herpes zoster","volume":"169","author":"Schmader","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1548787","article-title":"Repeated-dose toxicity and immunogenicity evaluation of a recombinant subunit COVID-19 vaccine (ZF2001) in rats","volume":"15","author":"Sun","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127122","article-title":"Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: a population-based survey","volume":"56","author":"Xia","year":"2025","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40122-019-0127-z","article-title":"The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study","volume":"8","author":"Yang","year":"2019","journal-title":"Pain Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1128\/jvi.68.7.4204-4211.1994","article-title":"Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex)","volume":"68","author":"Yao","year":"1994","journal-title":"J. Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1128\/jvi.67.1.305-314.1993","article-title":"Varicella-zoster virus glycoprotein gpI\/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system","volume":"67","author":"Yao","year":"1993","journal-title":"J. Virol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2228169","article-title":"The incidence of herpes zoster in China: a meta-analysis and evidence quality assessment","volume":"19","author":"Zhang","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal. Transduct Target Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1756776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:09:19Z","timestamp":1779430159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1756776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":21,"alternative-id":["10.3389\/fcimb.2026.1756776"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1756776","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1756776"}}